Acknowledgements
MYELOMA
The German Speaking Myeloma Multicenter Group (GMMG) initiated and designed the HD6 and HD7 trial. Sanofi, Chugai and Bristol Myers Squibb reviewed the manuscript. For the publication fee we acknowledge financial support by Deutsche Forschungsgemeinschaft within the funding programme “Open Access Publikationskosten” as well as by Heidelberg University.